Molpar (Paracetamol)

Paracetamol, the active ingredient in Molpar, is an analgesic presented as an intravenous solution for intravenous use. It provides rapid pain relief and reduces fever in hospitalized patients requiring immediate therapeutic effect, and is commonly employed in peri‑operative and emergency settings.

GNH USA supplies Molpar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution to healthcare facilities. Molpar is manufactured under EU GMP guidelines and is available for procurement by hospital pharmacies, procurement teams and clinical services.

Paracetamol, administered intravenously, acts as an analgesic and antipyretic across several clinical situations. - Acute pain: provides rapid, strong analgesia for postoperative or trauma‑related pain, facilitating early mobilization. - Fever: effectively lowers elevated body temperature in patients with infection, postoperative fever, or inflammatory conditions. - Headache: alleviates moderate to severe headache when oral administration is not feasible. - Musculoskeletal pain: reduces pain from musculoskeletal injuries, sprains or inflammation, supporting functional recovery. - Dental pain: offers prompt relief after dental surgery or severe odontogenic pain.

Paracetamol administered intravenously can be associated with a range of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild nausea may occur during or after infusion. - Vomiting: occasional vomiting following administration. - Injection site discomfort: transient pain or irritation at the infusion site. - Hypotension: mild, transient drop in blood pressure during rapid infusion. - Headache: mild headache may be reported. - Dizziness: occasional light‑headedness during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Hepatotoxicity: rare liver injury, especially with overdose or pre‑existing liver disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood disorders: rare cases of thrombocytopenia or leukopenia.

When using Molpar, clinicians should observe several precautions to ensure patient safety and maintain product integrity. - Assess liver function: avoid use in patients with severe hepatic impairment or active liver disease. - Monitor renal function: adjust therapy in patients with significant renal insufficiency. - Limit concurrent hepatotoxic agents: avoid combining with other drugs that may stress the liver. - Watch for hypersensitivity: discontinue if signs of allergic reaction such as rash or bronchospasm appear. - Use caution in alcohol users: chronic alcohol consumption increases risk of liver injury. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paracetamol may interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Other paracetamol‑containing products: risk of cumulative overdose and liver toxicity. - Chronic alcohol use: potentiates hepatotoxic effects and may lead to severe liver injury.

Moderate Interactions (Monitor Closely): - Warfarin: paracetamol can enhance anticoagulant effect, requiring INR monitoring. - Enzyme inducers (e.g., carbamazepine, phenytoin): may reduce paracetamol plasma levels, decreasing effectiveness. - Isoniazid: combined use may increase risk of hepatic adverse events.